Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quanterix Corporation
Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
- Digital Health
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- UmanDiagnostics AB